CAMBRIDGE, MASS. (WHDH) - Cambridge-based biotechnology company Moderna has begun testing a new version of its coronavirus vaccine.
The first participants have been dosed in the Phase 1 study of mRNA-1283, Moderna’s next-generation COVID-19 vaccine candidate, the company announced Monday.
“We are pleased to begin this Phase 1 study of our next generation COVID-19 vaccine candidate, mRNA-1283,” said Stéphane Bancel, Chief Executive Officer of Moderna. “Our investments in our mRNA platform have enabled us to develop this next generation vaccine candidate, which is a potential refrigerator-stable vaccine that could facilitate easier distribution and administration in a wider range of settings, including potentially for developing countries. We remain committed to helping address this ongoing public health emergency.”
The dose-ranging study will assess the safety and immunogenicity of mRNA-1283.
Moderna says that this vaccine is intended to be evaluated in futures studies for use as a booster dose for those previously vaccinated or seropositive as well as in a primary series for seronegative individuals.
(Copyright (c) 2024 Sunbeam Television. All Rights Reserved. This material may not be published, broadcast, rewritten, or redistributed.)